logo
  

BioLineRx: Pharmacoeconomic Study Shows Cost Benefits Of Using Motixafortide With G-CSF

BioLineRx Ltd. (BLRX) reported positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization agent on top of granulocyte colony stimulating factor, versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation.

"The compelling cost savings identified by this rigorously designed study strongly support the company's view that Motixafortide, in combination with G-CSF, can become the new standard of care as an upfront, or primary, therapy for all multiple myeloma patients undergoing autologous stem cell transplantation," said Philip Serlin, CEO.

BioLineRx said it remains on track to submit a New Drug Application to the FDA in the first half of next year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Caterpillar Inc. (CAT), a manufacturer of mining and construction equipment, reported Friday that fourth-quarter net income more than doubled to $2.12 billion or $3.91 per share from $780 million or $1.42 per share in the prior-year quarter. Excluding special items, adjusted net income for the quarter... United Airlines has opened its flight training school, United Aviate Academy, to bring out new pilots with a view to mainly empower women and people of color. The institute's first class of students is 80 percent women or people of color. This outpaces the airline's earlier goal to train about 5,000 new pilots at the school by 2030 with at least half being women or people of color. French telecom major Orange SA (ORAN) announced Friday that the company's Board of Directors, which met today, has appointed Christel Heydemann as the Chief Executive Officer of Orange with effect from April 4. The Board has asked Stéphane Richard to continue as Chairman & CEO until Heydemann takes...
RELATED NEWS
Follow RTT